Virtual planning and 3D‐printed guides for mandibular reconstruction: Factors impacting accuracy

Autor: Donald J. Annino Jr, Rosh K. Sethi, Elisabeth E. Hansen, Sylvia Horne, Tanujit Dey, Eleni M. Rettig, Ravindra Uppaluri, Jason I. Kass, Laura A. Goguen

Publikováno v: Laryngoscope Investigative Otolaryngology, Vol 7, Iss 6, Pp 1798-1807 (2022)

Abstract Objectives Examine accuracy and factors impacting accuracy for mandibular reconstruction with virtual surgical planning, 3D printed osteotomy guides and preoperatively bent mandibular reconstruction plate (VSP/3Dprinted‐guide/plate). Metho

Externí odkaz: https://doaj.org/article/e59e3fa62fa24aabbc8f0e72be1fa2a2

Supplementary Data from Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

Autor: Robert I. Haddad, Ravindra Uppaluri, Ann Marie Egloff, Cloud P. Paweletz, Megan E. Cavanaugh, Anupam M. Desai, Peter C. Everett, Roy B. Tishler, Danielle N. Margalit, Jonathan D. Schoenfeld, Jochen H. Lorch, Rosh K.V. Sethi, Eleni M. Rettig, Jason I. Kass, Laura A. Goguen, Donald J. Annino, Patrick H. Lizotte, Michelle Flynn, Jennifer M. Cutler, Charles T. Quinn, Vickie Y. Jo, Kristine Wong, Kee-Young Shin, Anne O'Neill, Glenn J. Hanna

Supplementary Data from Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16223d47d6a6a5a0f6e24e31f82882cf
https://doi.org/10.1158/1078-0432.22482441

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

Autor: Kristine S. Wong, Eleni M. Rettig, Ann Marie Egloff, Jason I. Kass, Danielle N. Margalit, Roy B. Tishler, Glenn J. Hanna, Michelle Flynn, Jochen H. Lorch, Charles T. Quinn, Megan E. Cavanaugh, Jennifer M. Cutler, Anne O'Neill, Donald J. Annino, Robert I. Haddad, Vickie Y. Jo, Ravindra Uppaluri, Cloud P. Paweletz, Kee-Young Shin, Laura A. Goguen, Jonathan D. Schoenfeld, Anupam M. Desai, Patrick H. Lizotte, Peter C. Everett, Rosh K. V. Sethi

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 28(3)

Purpose: Surgery often represents the best chance for disease control in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN). We investigated dual immune-checkpoint inhibition [anti–PD-1, nivolumab (N), and anti-KIR, liril

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b6179bc0a2a97497c6cb7859fb6569
https://pubmed.ncbi.nlm.nih.gov/34848533

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

Autor: Ryan S. Jackson, Mackenzie Daly, Jason I. Kass, Tiantian Li, Evisa Gjini, Youstina Hanna, Ian S. Hagemann, Liye Zhou, Douglas Adkins, Trevor J. Pugh, Gavin P. Dunn, Jessica Ley, Wade L. Thorstad, Glenn J. Hanna, Scott J. Rodig, Rachel S. Riley, Randal C. Paniello, Malachi Griffith, David Mulder, Tianxiang Lin, Ana Lako, Nicholas C. Spies, Matthew D. Stachler, Jason T. Rich, Rebecca D. Chernock, Loren S. Michel, Ravindra Uppaluri, Dorina Kallogjeri, Patrik Pipkorn, Robert I. Haddad, Vickie Y. Jo, Brian Nussenbaum, Jonathan D. Schoenfeld, Iulia Cirlan, Jay F. Piccirillo, Peter Oppelt, Paul Zolkind, Ann Marie Egloff, Obi L. Griffith, Zachary L. Skidmore, Erica K. Barnell, Tenny Mudianto, Katie M. Campbell

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 19
Clin Cancer Res
Int J Radiat Oncol Biol Phys

SUMMARYBackgroundPembrolizumab improved survival of patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this phase 2 trial were to determine if pembrolizumab administered to patients with resectable locall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8902376009ddebcea905e680e2c23c75
https://doi.org/10.1101/2020.03.18.20037846

TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2

Autor: Jason I. Kass, Kara S. Davis, Umamaheswar Duvvuri, Neal R. Godse, Carol A. Bertrand, Avani R. Vyas, Kevin Steehler, Douglas E. Holt, Sucheta Kulkarni, Carolyn Kemp, Jennifer R. Grandis, Anke Bill, L. Alex Gaither, Nayel I. Khan

Publikováno v: Genes, Chromosomes and Cancer. 56:460-471

TMEM16A, a Ca2+ -activated Cl- channel, contributes to tumor growth in breast cancer and head and neck squamous cell carcinoma (HNSCC). Here, we investigated whether TMEM16A influences the response to EGFR/HER family-targeting biological therapies. I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b3d1eec5e84306310a9c4eff7ff6423
https://doi.org/10.1002/gcc.22450